CUE Cue Biopharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1645460 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY401.9%
TTM net income YoY-448.5%
TTM EPS YoY-107.1%
Revenue 3-yr CAGR110.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-387.7%
Net margin-579.9%
FCF margin-143.7%
EBITDA margin-384.0%
Returns
ROE-800.4%
ROA-418.0%
ROIC (approx.)—
Asset turnover0.72x
Leverage & solvency
Liabilities / assets42.9%
Debt / equity0.00x
Current ratio3.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-314.6%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $27.47M | $9.29M |
| R&D expense | $37.74M | $36.30M |
| SG&A expense | $16.24M | $14.59M |
| Operating income | -$26.55M | -$41.50M |
| Interest expense | $100,000 | $100,000 |
| Income tax | $500,000 | $0 |
| Net income | -$26.60M | -$40.67M |
| EBITDA | -$25.59M | -$41.10M |
| EPS (basic) | -0.28 | -0.72 |
| EPS (diluted) | -0.28 | -0.72 |
| Weighted avg. shares (diluted) | 94.73M | 56.33M |
| Banking | ||
| Net interest income | -$357,000 | -$796,000 |
| Balance sheet | ||
| Cash & equivalents | $27.14M | $22.46M |
| Short-term investments | — | $0 |
| Receivables | $5.55M | $945,000 |
| Current assets | $36.98M | $25.14M |
| PP&E, net | $241,000 | $471,000 |
| Total assets | $42.21M | $32.19M |
| Current liabilities | $13.49M | $13.69M |
| Short-term debt | — | $37,000 |
| Long-term debt | — | $0 |
| Total debt | — | $37,000 |
| Total liabilities | $15.78M | $14.69M |
| Shareholders' equity | $26.43M | $17.50M |
| Net debt | — | -$22.42M |
| Shares outstanding | 3.22M | 61.82M |
| Cash flow statement | ||
| Operating cash flow | -$21.69M | -$36.33M |
| Capital expenditure | $177,000 | $66,000 |
| Free cash flow | -$21.86M | -$36.40M |
| Investing cash flow | $75,000 | $32,000 |
| Financing cash flow | $26.29M | $10.24M |
| Depreciation & amortization | $958,000 | $397,000 |
| Stock-based compensation | $4.74M | $6.85M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.